Loading...

    Explore
    • Policy Monitoring
    • Live Policy Feed
    • Billing Codes
    • Healthcare Providers
    • Health Insurance Payers
    • States
    • Service Lines
    • Taxonomy Codes
    Lookup tools
    • Billing Code Lookup
    • CPT Modifier Lookup
    • Provider Taxonomy Code Lookup
    • Healthcare Provider & Facility Lookup
    • Health Insurance Payer Lookup
    • Payer Contact Directory

    Policy & Benchmark Tools

    • Prior Authorization Lookup
    • Coverage Criteria Lookup
    • Timely Filing Lookup
    • Billing Code Reimbursement Rates
    • Payer Comparison Dashboard
    • Facility Comparison Dashboard
    • All tools

    Company

    • About OpenPayer
    • Data Sources
    • Request a Policy / Feedback
    • Trek Health
    OpenPayerby Trek Health
    LinkedInYouTube

    © 2026 Trek Health. All rights reserved.

    OpenPayer is built and maintained by Trek Health.

    v1.0.31
    OpenPayerPolicy UpdatesPharmacy & Specialty DrugsBlue Cross Blue Shield SC formulary Coverage Updat…
    Ask Trek AI about this page

    OpenPayer is powered by Trek Health's payer performance platform. Trek continuously ingests, validates, and normalizes Transparency in Coverage data alongside payer policies and other commercial payer data to create a structured payer intelligence foundation. OpenPayer uses this foundation to deliver personalized search results, dynamically generated policy pages, and tailored policy monitoring based on each user's payers, specialties, billing codes, and areas of interest. The same intelligence powers broader payer performance workflows, including reimbursement benchmarking, contract evaluation, payer negotiations, and financial decision-making.

    CurrentBlue Cross Blue Shield - South CarolinaPolicy N/A

    BlueCross Total Prescription Drug Formulary — Coverage Criteria

    Customize your policy alerts

    Sign up for all Blue Cross Blue Shield - South Carolina policy alerts

    Know when Blue Cross Blue Shield - South Carolina releases new policies or updates existing guidance.

    Monitor payer policy activity

    Receive email alerts as soon as relevant payer policies are published or updated.

    Governs the prescription drug formulary (Drug List) for BlueCross Total Medicare plan members, describing coverage, restrictions, and member options including prior authorization, step therapy, quantity limits, and exceptions. Affects plan members and prescribers using the BlueCross Total network pharmacies.

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyBlueCross Total Prescription Drug Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization from BlueCross Total when a drug is marked 'PA' before the prescription will be covered.
    SourceLink
    POLICY UPDATE CHANGES

    No material clinical or coverage changes in this revision.

    04/01/2026formulary effective/last updated date
    30 daystemporary supply when drug changed
    manyPA/PA NSO entries
    multipleQuantity limit examples
    6drug tiers
    26216Formulary ID

    Formulary Coverage Criteria

    General formulary coverage conditions

    Covered when ALL of the following are met

    Formulary listing and medical necessity: The drug is listed on the BlueCross Total formulary and is medically necessary for the member

    From formulary description (coverage contingent on medical necessity and formulary listing)

    Network pharmacy: The prescription is filled at a BlueCross Total network pharmacy

    Coverage requires fill at a BlueCross Total network pharmacy

    Compliance with plan rules and documentation: All applicable plan rules, documentation, and processes (including any prescriber supporting statement for exceptions) are submitted as required

    See formulary and exception procedures; prescriber must provide supporting statement when requesting an exception

    Policy Summary
    PayerBlue Cross Blue Shield - South Carolina
    PolicyBlueCross Total Prescription Drug Formulary — Coverage Criteria
    Policy CodePolicy N/A
    Change TypeNo material change
    Effective DateApr 1, 2026
    Last ReviewApr 1, 2026
    Next Review DateN/A
    Key ActionObtain prior authorization from BlueCross Total when a drug is marked 'PA' before the prescription will be covered.
    SourceLink
    On This Page
    Formulary Coverage CriteriaCoding, Metadata, and Formulary EntriesPrescriber and Provider RequirementsStep Therapy Rules and FlagsQuantity Limits by ProductDispensing Channel and Site-of-Care NotesGlossary and Symbol DefinitionsPolicy BackgroundPolicy Revision History
    Authorization and limits satisfied: If the drug listing specifies Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), or Non‑Extended Day Supply (NDS), those requirements must be met prior to coverage

    Refer to product Requirements/Limits column for drug‑specific controls

    Formulary coverage by tier and channel

    Coverage and cost-sharing depend on drug tier and dispensing channel; drugs are assigned to tiers and may have additional requirements.

    Tier assignment determines cost sharing: A drug is covered according to its assigned cost‑sharing tier (Tier 1–5) which determines member copay or coinsurance

    See tier descriptions and tier tables for exact copay/coinsurance by channel

    Dispensing channel affects cost sharing: Copay and coinsurance vary by dispensing channel (preferred/standard retail, mail order, long‑term care) and apply per the tier table

    Preferred/Standard Retail, Mail Order, and Long‑Term Care channels have distinct cost‑sharing rules

    Higher tiers may have special handling: Tier 5 (Specialty) drugs are high‑cost and may require special handling, monitoring, or site‑of‑care considerations

    Specialty tier membership often coincides with PA, QL, or site restrictions

    Coverage modifiers (PA/QL/NDS/ST)

    Specific drugs have usage limits or authorization requirements which modify coverage.

    Quantity limits (QL): Products annotated 'QL(...)' are subject to a maximum quantity allowed per specified time period (e.g., QL(30 EA per 30 days); QL(1000 GM per 30 days)) and claims exceeding the QL require review or prior authorizationExamples: QL(30 EA per 30 days); QL(1000 GM per 30 days)

    Exact QL values are listed with each product in the Requirements/Limits column

    Prior authorization (PA): Products marked 'PA' require prior authorization from BlueCross Total before coverage will be approved; failure to obtain PA may result in denial

    PA is shown in the Requirements/Limits column for specific formulations and strengths

    PA NSO / network/site restrictions: Items annotated 'PA NSO' indicate prior authorization and possible network/site or specialty channel limitations (may require site‑specific handling)

    PA NSO appears for selected specialty items (e.g., oncology, specialty injectables)

    Step therapy (ST / ST NSO): Products marked 'ST' or 'ST NSO' require that specified alternative(s) be tried and documented before the requested drug will be covered

    ST NSO indicates step therapy may apply for new starts only or with site restrictions

    Non‑Extended Day Supply (NDS): Items designated NDS have supply/days‑of‑service restrictions and must comply with the listed dispensing limits

    NDS flags appear for selected opioid and other controlled formulations

    Formulary management conditions

    Coverage is managed by product-specific Requirements/Limits; coverage is conditional when entries list PA and/or QL.

    PA‑listed products: Products marked 'PA' require prior authorization for coverage; providers must submit PA requests per payer procedures and document clinical indication

    Examples: BENLYSTA, DUPIXENT, many biologics and specialty agents list PA in Requirements/Limits

    Quantity‑limited products: Products with 'QL(...)' are limited to the specified quantity per time period; claims exceeding the stated QL may be denied or require PAe.g., QL(10 ML per 28 days); QL(104 ML per 365 days)

    Examples include COSENTYX, STELARA, SKYRIZI, DUPIXENT with explicit QL values

    Brand‑/label‑restricted products: Some entries restrict coverage to specific manufacturer‑labeled products (for example, 'Boehringer Ingelheim labeled products only'), limiting covered product to that manufacturer labeling

    Such restrictions appear for selected starter/maintenance adalimumab entries

    Drugs that are withdrawn from the market by the manufacturer or are removed by the FDA for safety or effectiveness reasons may be immediately removed from the formulary and not covered. When other formulary changes (for example adding a generic or biosimilar, adding PA/QL/ST restrictions, or moving a drug to a higher cost-sharing tier) are made that will affect members currently taking a drug, affected members must generally be notified at least 30 days before the change is effective; alternatively a member requesting a refill may receive a 30-day supply and notice of the change. Members and prescribers may request an exception to continue coverage where applicable.

    Some formulary tier rows explicitly identify items as Not Covered. For example, the Tier structure shows specific Tier 5 entries designated as Not Covered in certain positions (e.g., several Tier 5 Specialty rows are listed as Not Covered), so claims for products shown as 'Not Covered' in the tier table will not be paid under that tier.

    Certain starter packs and product listings are restricted to manufacturer-labeled products only. For example, multiple ADALIMUMAB-ADBM starter and maintenance entries include the note 'Boehringer Ingelheim labeled products only' in the Requirements/Limits column, meaning coverage is limited to those manufacturer‑labeled versions and may require the listed QL and PA conditions.

    Coding, Metadata, and Formulary Entries

    No procedure or diagnosis codes presentmixed
    No codes listed
    Formulary metadatamixed
    No codes listed
    Formulary product entries (selected examples)mixed
    VERQUVO TABLET 10MG, 2.5MG, 5MGDrug Tier = 3; Requirements/Limits = QL(30 EA per 30 days); PA.
    FARXIGA TABLET 10MG, 5MGDrug Tier = 3; Requirements/Limits = QL(30 EA per 30 days).
    JARDIANCE TABLET 10MG, 25MGDrug Tier = 3; Requirements/Limits = QL(30 EA per 30 days).
    dapagliflozin propanediol tablet 10mg, 5mgDrug Tier = 3; Requirements/Limits = QL(30 EA per 30 days).
    AUSTEDO XR TABLET EXTENDED RELEASE 24 HOUR 12MG-48MG, 6MGDrug Tier = 5; Requirements/Limits = QL(30 EA per 30 days); PA.
    AUSTEDO TABLET 12MG, 6MG, 9MGDrug Tier = 5; Requirements/Limits = QL(120 EA per 30 days); PA.
    INGREZZA CAPSULE 60MG, 80MGDrug Tier = 5; Requirements/Limits = QL(30 EA per 30 days); PA.
    INGREZZA CAPSULE 40MGDrug Tier = 5; Requirements/Limits = QL(60 EA per 30 days); PA.
    NUEDEXTA CAPSULE 20MG; 10MGDrug Tier = 5; Requirements/Limits = PA.
    VEOZAH TABLET 45MGDrug Tier = 4; Requirements/Limits = QL(30 EA per 30 days); PA.
    1–10 of 20
    1/2
    Quantity limitsmixed
    QL(60 EA per 30 days)Quantity limit applied to selected proton pump inhibitors (e.g., esomeprazole, lansoprazole, omeprazole, pantoprazole, rabeprazole).
    Prior Authorization flagsmixed
    PAPrior Authorization required for specified drugs (e.g., CERDELGA, CHOLBAM, EVRYSDI, FABRAZYME, ONPATTRO, PROLASTIN-C, REVCOVI, sapropterin).
    Additional QL entriesmixed
    QL(91 EA per 91 days)Quantity limit applied to certain contraceptive products.
    QL(240 ML per 30 days)Quantity limit for EVRYSDI solution reconstituted.
    QL(30 EA per 30 days)Quantity limit for PYRUKYND taper pack.
    QL(120 EA per 30 days)Quantity limit for PYRUKYND 50 mg tablets.
    No procedure/diagnosis codes in this excerptmixed
    No codes listed
    inv-15: Quantity Limits examples
    QL(30 EA per 90 days)Example: JOURNAVX TABLET 50MG has QL(30 EA per 90 days)
    QL(60 EA per 30 days)Example: celecoxib capsule has QL(60 EA per 30 days)
    QL(1000 GM per 30 days)Example: diclofenac sodium gel 1% has QL(1000 GM per 30 days)
    QL(4 EA per 28 days)Example: buprenorphine patch weekly has QL(4 EA per 28 days)
    inv-16: Quantity Limits examples
    QL(30 GM per 30 days)Example: lidocaine/prilocaine cream listed with QL(30 GM per 30 days)
    QL(150 GM per 30 days)Example: lidocaine ointment 5% listed with QL(150 GM per 30 days)
    QL(1800 ML per 28 days)Example: linezolid suspension reconstituted 100mg/5ml has QL(1800 ML per 28 days)
    inv-17: Quantity Limits examples — exact QL values present
    QL(10 EA per 30 days)Per formulary examples: perampanel suspension and VALTOCO dose packs show QL(10 EA per 30 days)
    QL(300 EA per 30 days)Clonazepam OD and related entries show QL examples up to QL(300 EA per 30 days)
    QL(60 EA per 30 days)Desvenlafaxine ER 25/50mg shows QL(30/60/120 patterns) and other exact QLs like QL(60 EA per 30 days)
    inv-18: Examples of quantity limits shown in list (sample values)
    QL(450 ML per 30 days)Ondansetron solution listed with QL(450 ML per 30 days)
    QL(3 ML per 28 days)NURTEC and other injectables show small-ML QLs like QL(3 ML per 28 days)
    QL(18 EA per 30 days)Rizatriptan listings include QL(18 EA per 30 days) as an example
    inv-19: Quantity limits examples — ZEJULA, VORANIGO examples
    ZEJULA TABLET 100MG — QL(30 EA per 30 days)ZEJULA 100mg is listed with QL(30 EA per 30 days); PA NSO noted in the table
    VORANIGO TABLET 10MG — QL(60 EA per 30 days)VORANIGO 10mg is listed with QL(60 EA per 30 days); PA NSO indicated
    inv-20: Examples of Quantity Limits — additional product-specific QLs
    BARACLUDE SOLUTION — QL(600 ML per 30 days)BARACLUDE solution entry lists QL(600 ML per 30 days)
    MAVYRET PACKET — 560 EA per 365 daysMAVYRET packet listed with 560 units per 365 days (QL at product level)
    sofosbuvir/velpatasvir — QL(84 EA per 365 days)sofosbuvir/velpatasvir tablet listed with QL(84 EA per 365 days); PA
    inv-21: TRULICITY limit
    TRULICITY — QL(2 ML per 28 days)TRULICITY injection listed with QL(2 ML per 28 days); PA noted
    inv-22: MOUNJARO limit (partial)
    MOUNJARO — QL(2 ML per 28 days)MOUNJARO injection entries show QL(2 ML per 28 days) in the formulary
    OZEMPIC — QL(3 ML per 28 days)OZEMPIC injection listed with QL(3 ML per 28 days); PA
    inv-23: OZEMPIC limit — QL(3 ML per 28 days) and RYBELSUS 14/7mg
    OZEMPIC — QL(3 ML per 28 days)OZEMPIC injection 2mg/3mL etc. listed with QL(3 ML per 28 days); PA
    RYBELSUS 14/7mg — QL(30 EA per 30 days)RYBELSUS 14mg/7mg tablets listed with QL(30 EA per 30 days); PA
    inv-24: RYBELSUS 14/7mg & 3mg limits
    RYBELSUS 14/7mg — QL(30 EA per 30 days)RYBELSUS 14mg and 7mg strengths shown with QL(30 EA per 30 days)
    RYBELSUS 3mg — QL(60 EA per 365 days)RYBELSUS 3mg listed with QL(60 EA per 365 days); PA
    inv-25: dabigatran limit
    dabigatran etexilate — QL(60 EA per 30 days)Dabigatran etexilate capsule entries list QL(60 EA per 30 days)
    inv-26: ELIQUIS starter pack limit
    ELIQUIS starter pack — QL(148 EA per 365 days)ELIQUIS starter pack tablet therapy pack listed with QL(148 EA per 365 days)
    inv-27: XARELTO starter/suspension/tablet limits
    XARELTO starter pack — QL(102 EA per 365 days)XARELTO starter pack therapy packs are shown with QL(102 EA per 365 days)
    XARELTO suspension — QL(600 ML per 30 days)XARELTO suspension reconstituted listed with QL(600 ML per 30 days)
    XARELTO tablet 10/20mg — QL(30 EA per 30 days)XARELTO 10mg and 20mg tablets listed with QL(30 EA per 30 days)
    inv-31: Sample QL examples
    QL(30 EA per 30 days)Common sample QL: QL(30 EA per 30 days) appears across multiple product entries (e.g., many tablets)
    QL(120 EA per 30 days)Example QL pattern: QL(120 EA per 30 days) appears for select products
    QL(300 GM per 30 days)Topical example: QL(300 GM per 30 days) for diclofenac sodium gel 3% and similar formulations
    inv-31: Sample QL examples repeated
    QL(30 EA per 30 days)Common QL example for many tablets across sections
    QL(120 EA per 30 days)Common higher QL example (e.g., certain extended-release or higher-dose tablets)
    QL(300 GM per 30 days)Common topical mass-based QL example (e.g., diclofenac gel 3%)

    Prescriber and Provider Requirements

    Prior Authorization

    Prior Authorization Required

    Some covered drugs require prior authorization before the plan will pay. Prescribers must obtain prior authorization (PA) per Blue Cross Blue Shield - South Carolina procedures for drugs flagged PA or PA NSO in the formulary. Failure to obtain required PA may result in denial of coverage.

    • PA and PA NSO flags in the formulary indicate an authorization is required prior to dispensing.
    • PA NSO items (Prior Authorization — Network/Site Only) require submission and approval per the plan's network/site-specific process.
    • If PA is not obtained, the claim may be denied and the plan may not cover the drug.
    Prior Authorization

    PA and PA NSO for High‑Tier / Specialty Drugs

    Many specialty, oncology, high‑tier and selected branded agents have PA or PA NSO requirements and/or quantity limits (QL). Examples in the formulary include high‑cost agents such as BRIVIACT, EPIDIOLEX, ARIKAYCE, many antineoplastics (e.g., IBRANCE, XALKORI), specialty biologics (e.g., STELARA, COSENTYX), and other products annotated PA NSO.

    • Selected high‑tier examples: BRIVIACT, EPIDIOLEX, DIACOMIT, XCOPRI (many marked PA NSO).
    • Specialty/oncology examples with PA NSO: IBRANCE, XALKORI, XPOVIO, many oncology therapy packs.
    • Immunologic and biologic specialty agents (e.g., DUPIXENT, STELARA, SKYRIZI) list PA and often QL entries.
    Documentation Required

    Follow PA, QL and Step Therapy Rules

    Quantity limits (QL), step therapy (ST or ST NSO), and PA entries shown in the formulary are binding rules for coverage. Providers must follow the Requirements/Limits column and use the formulary symbol definitions in the introduction when preparing PA requests and when submitting claims.

    • QL entries specify the allowed amount and time period (for example, QL(30 EA per 30 days)).
    • ST and ST NSO indicate step therapy requirements; ST NSO may apply to new starts only or network/site‑specific starts.
    • Use the introduction pages to interpret symbols (PA, QL, ST, NDS, B/D).
    Denial Risk

    Denial Risk for Missing PA or Exceeding QL

    Prior authorization and quantity‑limit rules are common denial triggers. Claims for drugs listed with PA, PA NSO, or with exceeded QL may be denied if the required authorization or documentation is not submitted.

    • Denials may occur when PA is missing or when the dispensed quantity exceeds the QL specified in the formulary.
    • PA NSO items may require additional network/site‑specific documentation — check plan procedures before submitting.
    • When requesting an exception, the prescriber must provide a supporting statement explaining the medical rationale; expedited review may apply when clinically necessary.
    Documentation Required

    Exceptions and Prescriber Supporting Statement

    If you seek an exception to a formulary rule (e.g., to waive PA, ST, or a quantity limit, or to request tiering/coverage level changes), the prescriber must submit a supporting statement describing the medical necessity. Standard decisions are generally made within 72 hours of receiving the prescriber's documentation; expedited decisions within 24 hours when appropriate.

    • Exceptions may permit coverage of non‑formulary drugs or waive PA/QL/ST when the prescriber documents that alternatives are ineffective or would cause harm.
    • Prescriber supporting statement should explain why the member requires the exception and include relevant clinical information.
    Billing Rule

    Cost Sharing and Dispensing Channel

    Apply member cost‑sharing per the plan's tier and dispensing channel (retail, mail order, LTC) as shown in the formulary. Cost sharing (copay, coinsurance, deductible) varies by tier and by channel and must be applied even when PA is required.

    • Check the formulary header and channel‑specific sections for the applicable copay/coinsurance and deductible rules.
    • A PA approval does not change the applicable tier/cost‑sharing unless an approved tiering exception specifies otherwise.

    Step Therapy Rules and Flags

    Step therapy ruleNotes / Explanation
    Member must trial specified drugs in the sequence required by step therapy before the plan will cover the subsequent drug
    FlagMeaning / When applied
    ST or ST NSO
    Step Therapy (ST) indicates a required trial of preferred agent(s); ST NSO indicates Step Therapy for New Starts Only or related new-start restrictions as defined in Requirements/Limits key
    Product examplesRequirements/Limits noted
    ARIKAYCE suspension; TEFLARO injection; BRIVIACT formulations; EPIDIOLEX solution
    Marked with PA or PA NSO in Requirements/Limits — prior authorization (possibly network/site specific) required before coverage
    ST NSO examplesRequirements/Limits entry
    FYCOMPA suspension; EXXUA titration and maintenance tablets; FETZIMA titration pack and strengths
    Requirements/Limits = PA NSO or ST NSO as listed (indicating step therapy/new-start and/or PA NSO handling)
    FETZIMA entryRequirements/Limits
    FETZIMA capsule extended release (120mg, 20mg, 40mg, 80mg) and FETZIMA titration pack
    Requirements/Limits = QL(30 EA per 30 days) for strengths; FETZIMA titration pack = QL(56 EA per 365 days); both list ST NSO
    FETZIMA titration packControls noted
    FETZIMA TITRATION PACK CAPSULE ER 24 HOUR THERAPY PACK
    Requirements/Limits = QL(56 EA per 365 days); ST NSO
    Presence of step sequencesDocument excerpt notes
    No explicit multi-step sequences (drug A → drug B) are shown in the provided excerpt
    Individual products are marked with PA and/or QL and some with ST/ST NSO; the introduction explains step therapy concept and symbols
    Products with ST or ST NSOExamples / Notes
    RYTARY capsule extended release
    Requirements/Limits = ST (as listed); FANAPT titration packs show ST NSO and QL entries in the table
    Antiviral / antidiabetic examplesRequirements/Limits
    MAVYRET, sofosbuvir/velpatasvir, VOSEVI (HCV agents); MOUNJARO, OZEMPIC, TRULICITY, RYBELSUS (antidiabetics)
    These are marked with PA and various QL entries; no explicit multi-step sequences are provided in the excerpt
    Hematopoietic agentsRequirement
    NEULASTA ONPRO kit; PROCRIT injection; RETACRIT injection
    Requirements/Limits = PA (prior authorization required) as listed
    High-cost injectables (PCSK9, biologics)Controls noted
    PRALUENT injection; REPATHA injection; TRYNGOLZA injection; COSENTYX/DUPIXENT biologics
    Requirements/Limits include QL and PA (e.g., PRALUENT QL(2 ML per 28 days); PA; COSENTYX QL(10 ML per 28 days); PA), which may imply step or prior requirements before approval
    Topical diclofenac entryRequirements/Limits
    diclofenac sodium gel 3%
    Requirements/Limits = QL(300 GM per 30 days); ST (step therapy flag present)
    Products annotated 'ST'Examples shown
    diclofenac sodium gel 3%; RELISTOR injection/tablet formulations; XERMELO (where listed)
    These entries include 'ST' in the Requirements/Limits column indicating step therapy applies per the formulary table
    Tiering and implied step editsNotes
    Many products are assigned to tiers (Tier 1-5) and higher tiers may be subject to step edits
    The document lists tiers and Requirements/Limits; while tiering can imply prior/step edits, explicit step sequences are not detailed in the excerpt
    High-tier specialty productsAuthorization / step comments
    Multiple specialty biologics and injectables (e.g., LUPRON DEPOT, BENLYSTA, COSENTYX, many immunologics; adalimumab starter/maintenance packs)
    These entries frequently list PA and QL; specific step therapy rules are not detailed in the provided excerpt but PA/QL may function alongside step edits
    Starter-pack productsCoverage / limits
    ADALIMUMAB-ADBM starter packages (Crohns/UC/HS; Psoriasis/Uveitis) and other labeled starter packs
    Requirements/Limits distinguish starter vs maintenance packs (QL and PA) and may include manufacturer-labeled-product restrictions (e.g., 'Boehringer Ingelheim labeled products only'), affecting coverage

    Quantity Limits by Product

    inv-132: Cablivi and related QLs
    Cablivi30 tablets per 30 days (example in formulary and introduction)
    linezolid suspension 100mg/5mlQL(1800 ML per 28 days) as listed in product entries
    linezolid tablet 600mgQL(56 EA per 28 days) shown in formulary
    inv-133: diclofenac and topical QLs
    diclofenac sodium gel 1%QL(1000 GM per 30 days) listed for 1% gel
    diclofenac sodium gel 3%QL(300 GM per 30 days) listed for 3% gel (also shows ST)
    calcipotriene cream/ointment 0.005%QL(120 GM per 30 days) shown for cream/ointment
    inv-134: JOURNAVX and celecoxib examples
    JOURNAVX TABLET 50MGQL(30 EA per 90 days)
    celecoxib capsuleQL(60 EA per 30 days)
    diclofenac sodium dr tabletNo QL for some oral diclofenac forms (per table)
    inv-135: celecoxib and buprenorphine patch QLs
    celecoxib capsuleQL(60 EA per 30 days) shown in analgesics section
    buprenorphine patch weeklyQL(4 EA per 28 days) and NDS indicated
    fentanyl patchSome fentanyl patches listed without QL; other transmucosal forms may have PA/NDS
    inv-136: buprenorphine patch weekly examples
    buprenorphine patch weeklyQL(4 EA per 28 days) listed for weekly patches
    fentanyl patch 72 hourEntries appear under tier 4; various requirements apply
    ketorolac tabletQL(20 EA per 30 days) example in analgesic section
    inv-137: lidocaine/prilocaine and ointment QLs
    lidocaine/prilocaine creamQL(30 GM per 30 days); PA noted for certain formulations
    lidocaine ointment 5%QL(150 GM per 30 days) listed; premium ointment similarly limited
    lidocaine/prilocaine cream 2.5%/2.5%30 GM per 30 days shown as QL
    inv-138: lidocaine ointment and similar QLs
    lidocaine ointment 5%QL(150 GM per 30 days) (product-level entry)
    premium lidocaine ointment 5%Also shows QL(150 GM per 30 days) in formulary listings
    clotrimazole creamQL(90 GM per 30 days) example for antifungal topical agents
    inv-139: lidocaine/prilocaine cream 2.5%;2.5% — 30 GM
    lidocaine/prilocaine cream 2.5%/2.5%QL(30 GM per 30 days) as listed
    calcipotriene solution 0.005%QL(60 ML per 30 days) shown for solution form
    fluorouracil cream 5%QL(40 GM per 30 days) indicated for some strengths
    inv-140: lidocaine ointment 5% — 150 GM
    lidocaine ointment 5%QL(150 GM per 30 days) (repeated product-level entry)
    tacrolimus ointmentListed without QL in some entries; other topicals have QLs
    calcipotriene cream/ointmentQL(120 GM per 30 days) for cream/ointment
    inv-141: linezolid suspension QL
    linezolid suspension 100mg/5mlQL(1800 ML per 28 days) as listed in formulary
    linezolid tablet 600mgQL(56 EA per 28 days) listed for tablet form
    metronidazole vaginal gelNo QL shown for some formulations in same section
    inv-142: linezolid tablet and vancomycin capsule QLs
    linezolid tablet 600mgQL(56 EA per 28 days)
    vancomycin hydrochloride capsule 125mgQL(120 EA per 30 days)
    vancomycin hydrochloride capsule 250mgQL(240 EA per 30 days)
    inv-143: vancomycin capsule 125mg — 120 EA
    vancomycin hydrochloride capsule 125mgQL(120 EA per 30 days)
    vancomycin hydrochloride capsule 250mgQL(240 EA per 30 days)
    vancomycin injection formsInjection formulations shown separately without the same capsule QLs
    inv-144: vancomycin capsule 250mg — 240 EA
    vancomycin hydrochloride capsule 250mgQL(240 EA per 30 days)
    vancomycin hydrochloride capsule 125mgQL(120 EA per 30 days)
    other antibacterial capsulesOther oral antibacterials listed with various QLs or none
    inv-145: varenicline and cessation agent QLs
    varenicline (packs/tablets)QL(504 EA per 365 days) listed for varenicline starting month pack/tablets
    NICOTROL NS SOLUTIONQL(360 ML per 365 days) also listed in smoking cessation section
    TYRVAYA SOLUTIONQL(8.4 ML per 30 days) for TYRVAYA
    inv-146: NICOTROL & TYRVAYA QLs
    NICOTROL NS SOLUTION 10MG/MLQL(360 ML per 365 days)
    TYRVAYA SOLUTION 0.03MG/ACTQL(8.4 ML per 30 days)
    varenicline packQL(504 EA per 365 days)
    inv-147: biologic injection QL examples
    AIMOVIG 140MG/ML1 ML per 28 days for AIMOVIG 140mg/ml (AIMOVIG referenced in other MIG entries)
    AIMOVIG 70MG/ML2 ML per 28 days for AIMOVIG 70mg/ml
    BENLYSTA / COSENTYX / DUPIXENT examplesMultiple biologic formulations show ML-based QLs; see COSENTYX QL(10 ML per 28 days), DUPIXENT QL(4.56 ML per 28 days)
    inv-148: multiple formulary entries — various QL values
    Multiple QL patternsFormulary shows many exact QL values (EA/ML/GM) across therapeutic classes, e.g., QL(10 EA per 30 days); QL(300 EA per 30 days); QL(2160 ML per 30 days)
    Examples by routeOral tablets often use EA per 30 days; liquids use ML per 30 days; topicals use GM per 30 days
    Provider actionProviders should reference the product-specific Requirements/Limits column for exact QL enforcement
    inv-149: desvenlafaxine QLs
    desvenlafaxine er 100mgQL(120 EA per 30 days) listed for desvenlafaxine ER 100mg
    desvenlafaxine er 25mg/50mgQL(30 EA per 30 days) for 25mg and 50mg strengths
    DRIZALMA / duloxetine examplesOther antidepressant entries show QLs such as QL(60 EA per 30 days) and QL(90 EA per 30 days)
    inv-150: desvenlafaxine 25/50mg QLs
    desvenlafaxine er 25mg, 50mgQL(30 EA per 30 days) listed for these strengths
    desvenlafaxine er 100mgQL(120 EA per 30 days) for 100mg strength
    duloxetine examplesDuloxetine entries show QL(60–90 EA per 30 days) depending on strength
    inv-151: FETZIMA titration pack QL
    FETZIMA TITRATION PACKQL(56 EA per 365 days); ST NSO noted for titration pack
    FETZIMA maintenanceQL(30 EA per 30 days) for maintenance capsule strength entries
    ST NSO noteTitration packs may include ST NSO flags — see product entry
    inv-152: ondansetron solution QL
    ondansetron solutionQL(450 ML per 30 days) listed for ondansetron solution
    ondansetron tablets/ODTTablets/ODT are listed with B/D or no QL depending on formulation
    dronabinol exampleDronabinol shows QL(60 EA per 30 days); PA
    inv-153: AIMOVIG QLs
    AIMOVIG 140MG/ML1 ML per 28 days listed for AIMOVIG 140mg/ml
    AIMOVIG 70MG/ML2 ML per 28 days listed for AIMOVIG 70mg/ml
    Migraine biologic QL noteML-based QLs apply to migraine biologics; verify per product entry
    inv-154: AIMOVIG 70MG/ML QL
    AIMOVIG 70MG/ML2 ML per 28 days for AIMOVIG 70mg/ml
    AIMOVIG 140MG/ML1 ML per 28 days for AIMOVIG 140mg/ml
    NURTEC / QULIPTA examplesOther migraine agents list EA-based QLs (e.g., QL(18 EA per 30 days) for some oral triptans)
    inv-155: POMALYST, LAZCLUZE, IMBRUVICA QLs
    POMALYST capsules 1mg/2mgQL(30 EA per 30 days) listed for POMALYST capsules
    LAZCLUZE tablet 80mgQL(60 EA per 30 days) listed for LAZCLUZE 80mg
    IMBRUVICA capsule 140mgQL(120 EA per 30 days) listed for IMBRUVICA 140mg
    inv-156: LAZCLUZE & oncology QLs
    LAZCLUZE 80mgQL(60 EA per 30 days) shown for LAZCLUZE 80mg; PA NSO for some strengths
    NERLYNX 40mgQL(180 EA per 30 days) listed for NERLYNX 40mg
    SCEMBLIX / RETEVMO patternsTargeted oncology agents show strength-dependent QLs (e.g., 60–240 EA per 30 days)
    inv-157: IMBRUVICA, NERLYNX, SCEMBLIX QLs
    IMBRUVICA capsule 140mgQL(120 EA per 30 days); PA NSO for some product forms
    NERLYNX tablet 40mgQL(180 EA per 30 days); PA NSO for some oncology agents
    SCEMBLIX tabletsQL range 60–240 EA per 30 days depending on strength
    inv-158: SCEMBLIX and RETEVMO QLs
    SCEMBLIXQL(60-240 EA per 30 days) depending on strength
    RETEVMOQL(60-90 EA per 30 days) depending on strength
    PIQRAY / TAGRISSO patternsOther targeted therapies show QLs and PA NSO flags per entry
    inv-161: ZEJULA QL
    ZEJULA TABLET 100MG30 EA (QL(30 EA per 30 days)) listed for ZEJULA 100mg
    ZEJULA other strengthsOther strengths may have different QLs/PA NSO flags per table
    oncology QL noteMany oncology agents are strength- and pack-specific for QLs
    inv-162: VORANIGO QL
    VORANIGO TABLET 10MGQL(60 EA per 30 days) listed for VORANIGO 10mg; PA NSO noted
    VORANIGO 40mgPA NSO indicated for other strengths
    oncology product noteRefer to product row for exact QL and PA/NSO designations
    inv-163: quetiapine formulation QLs
    quetiapine formulationsQL(60 EA per 30 days) or QL(90 EA per 30 days) depending on formulation (ER vs immediate-release)
    paliperidone erExamples show QL(30–60 EA per 30 days) varying by product
    clozapine examplesClozapine QLs range widely (e.g., 120–270 EA per 30 days) per strength
    inv-164: VERSACLOZ suspension QL
    VERSACLOZ SUSPENSION 50MG/MLQL(540 ML per 30 days) listed for VERSACLOZ suspension
    clozapine tablet QLsClozapine tablet forms show large EA-per-month QLs depending on strength
    antipsychotic QL patternLiquid suspensions and specialty formulations use ML-based QLs
    inv-165: BARACLUDE solution QL
    BARACLUDE SOLUTION 0.05MG/MLQL(600 ML per 30 days) listed for BARACLUDE solution
    BARACLUDE product-level noteProduct-level entry repeats 600 ML per 30 days as the QL
    entecavir / lamivudine examplesOther HBV agents show QLs like QL(30 EA per 30 days) for tablets
    inv-166: BARACLUDE solution — 600
    BARACLUDE SOLUTION 0.05MG/ML — 600 MLQL(600 ML per 30 days) (product-level entry)
    PREVYMIS / valganciclovir examplesOther antiviral solutions and packets have specific QLs noted nearby
    Formulary noteAdhere to product-specific QLs when submitting claims
    inv-167: MAVYRET & sofosbuvir/velpatasvir QLs
    MAVYRET PACKET 50MG;20MG560 EA per 365 days listed for MAVYRET packet
    MAVYRET TABLET 100MG;40MG336 EA per 365 days listed for MAVYRET tablets
    sofosbuvir/velpatasvirQL(84 EA per 365 days) listed; PA indicated
    inv-167b: MAVYRET packet/tablet QLs
    MAVYRET PACKET560 EA per 365 days (packet-level QL)
    MAVYRET TABLET336 EA per 365 days (tablet-level QL)
    VOSEVI / sofosbuvir combosQL(84 EA per 365 days) for full-course HCV regimens
    inv-169: ISENTRESS and zidovudine QLs
    ISENTRESS TABLET 400MGQL(60 EA per 30 days) listed for ISENTRESS 400mg
    zidovudine syrup 50mg/5mlQL(1920 ML per 30 days) listed for zidovudine syrup
    HIV regimen QL noteMany antiretroviral agents have 30 EA per 30 days or ML-based QLs depending on form
    inv-171: zidovudine syrup QL
    zidovudine syrup 50mg/5mlQL(1920 ML per 30 days) listed for zidovudine syrup
    abacavir solution exampleAbacavir solution shows QL(960 ML per 30 days) in HIV section
    tablet QL patternsTablets generally listed as EA per 30 days (e.g., 30 EA per 30 days)
    inv-172: MOUNJARO & OZEMPIC QLs
    MOUNJARO INJECTIONQL(2 ML per 28 days) listed for MOUNJARO injection
    OZEMPIC INJECTIONQL(3 ML per 28 days) listed for OZEMPIC injection
    TRULICITYTRULICITY QL(2 ML per 28 days) referenced elsewhere
    inv-173: OZEMPIC and RYBELSUS examples
    OZEMPIC INJECTIONQL(3 ML per 28 days) listed for OZEMPIC (2mg/3mL, 4mg/3mL, 8mg/3mL)
    RYBELSUS 14/7mgQL(30 EA per 30 days) for RYBELSUS 14/7mg
    RYBELSUS 3mgQL(60 EA per 365 days) for RYBELSUS 3mg
    inv-174: JANUVIA QL
    JANUVIA TABLET 100MGQL(30 EA per 30 days) listed for JANUVIA 100mg (and other strengths)
    JANUVIA dosing noteMultiple JANUVIA strengths share QL(30 EA per 30 days)
    sitagliptin examplesSee product row for exact QL and tiering information
    inv-175: PAXLOVID pack QL
    PAXLOVID therapy packQL(11 to 30 EA per 5 days) depending on pack specification (examples in antiviral section)
    LAGEVRIO exampleLAGEVRIO QL(40 EA per 5 days) shown for 200mg capsule pack
    antiviral pack noteTherapy packs use short-period QLs (per 5-day course) as listed
    inv-177: OZEMPIC & TRULICITY QLs
    OZEMPIC INJECTIONQL(3 ML per 28 days) (reaffirmed in product entries)
    TRULICITY INJECTIONQL(2 ML per 28 days) listed for TRULICITY (product-level)
    MOUNJARO INJECTIONQL(2 ML per 28 days) for MOUNJARO entries
    inv-178: TRULICITY QL
    TRULICITY INJECTIONQL(2 ML per 28 days) (product-level entry)
    TRULICITY strengthsMultiple strengths (0.75,1.5,3,4.5 mg/0.5mL) share same ML-per-28-day QL
    PA notePA is noted alongside TRULICITY in the Requirements/Limits column
    inv-179: RYBELSUS QLs
    RYBELSUS 14/7mgQL(30 EA per 30 days)
    RYBELSUS 3mgQL(60 EA per 365 days)
    RYBELSUS PA notePA indicated alongside RYBELSUS entries
    inv-180: RYBELSUS 3mg limit
    RYBELSUS 3mgQL(60 EA per 365 days) listed for 3mg strength
    RYBELSUS 14/7mgQL(30 EA per 30 days) for higher strengths
    PA indicatedPA indicated for RYBELSUS in product listing
    inv-181: dabigatran QL
    dabigatran etexilate capsuleQL(60 EA per 30 days) listed for dabigatran etexilate capsules
    ELIQUIS tablet examplesELIQUIS tablets have multiple QLs for different pack types (e.g., 60 EA per 30 days for 2.5mg)
    anticoagulant QL noteStarter packs and maintenance packs have distinct QLs (see product rows)
    inv-182: XARELTO starter/suspension/tablet QLs
    XARELTO STARTER PACKQL(102 EA per 365 days) for starter pack therapy packs
    XARELTO SUSPENSION RECONSTITUTEDQL(600 ML per 30 days) for suspension formulation
    XARELTO 10/20mg tabletsQL(30 EA per 30 days) for 10mg and 20mg tablets
    inv-183: XARELTO suspension limit
    XARELTO SUSPENSIONQL(600 ML per 30 days)
    XARELTO TABLET 10/20MGQL(30 EA per 30 days)
    XARELTO STARTER PACKQL(102 EA per 365 days)
    inv-184: XARELTO tablet 10/20mg limit
    XARELTO TABLET 10MG, 20MGQL(30 EA per 30 days)
    XARELTO 2.5MGQL(360 EA per 30 days) shown for lower-dose tablet packings
    starter/suspension noteSee specific product row for starter pack vs maintenance QLs

    Dispensing Channel and Site-of-Care Notes

    Billing Rule

    Apply channel‑specific copay/coinsurance (retail, mail order, LTC)

    Retail, mail order, and long‑term care dispensing channels have differing copay/coinsurance amounts by tier; apply the formulary's channel‑specific cost‑sharing when processing prescriptions.

    • Mail order and long‑term care cost‑sharing and supply rules are listed separately.
    • Tier‑based copays/coinsurance differ by channel.
    Note

    Check site‑of‑care/network requirements for PA NSO items

    PA NSO annotations may indicate network/site specialty restrictions (for example many PA NSO oncology and specialty entries); providers should verify site‑of‑care requirements with the plan when placing orders for infusion or specialty administration.

    • LUPRON DEPOT and many oncology therapy packs are marked PA NSO.
    • PA NSO can imply network or site‑of‑care constraints though exact rules may not be fully specified in this excerpt.

    Glossary and Symbol Definitions

    Policy Background

    The formulary groups drugs by therapeutic area and includes brand, generic, biological, and biosimilar products. Coverage is determined by whether the drug is on the BlueCross Total Drug List, whether it is medically necessary, the assigned cost-sharing tier, and any product-specific controls such as Prior Authorization (PA), Quantity Limits (QL), Step Therapy (ST), or Non-Extended Day Supply (NDS). Generic drugs share the same active ingredient as brand-name drugs, and biosimilars are alternatives to original biological products that may be subject to interchangeability and state law considerations.

    Policy Revision History

    2026-05-01formulary_effective

    Formulary version 12 became effective for the plan (Effective Date: 05/01/2026).

    2026-04-01last_updatedLatest

    Formulary document last updated (Last Updated: 04/01/2026).

    2026-05-01formulary_effective

    Formulary (Formulary ID: 26216, Version: 12) shows an effective date of 05/01/2026 for this version.

    2026-04-01metadata_last_updatedLatest

    Document metadata indicates 'Last Updated: 04/01/2026' for Formulary ID 26216, Version 12.